Literature DB >> 31401234

The expression of gastrointestinal differentiation markers in extrahepatic cholangiocarcinoma: clinicopathological significance based on tumor location.

Kazuyuki Ishida1, Mitsumasa Osakabe1, Makoto Eizuka1, Seigo Tai1, Ryo Sugimoto1, Yasuko Fujita1, Hirokatsu Katagiri2, Takeshi Takahara2, Noriyuki Uesugi1, Hiroyuki Nitta2, Akira Sasaki2, Tamotsu Sugai3.   

Abstract

The expression of gastrointestinal differentiation markers is associated with the tumorigenesis and prognosis of digestive cancers. However, little is known about the significance of gastrointestinal differentiation marker profiles in patients with extrahepatic cholangiocarcinoma (CCA), which is classified as perihilar and distal CCA. The purpose of this study was to clarify the role of gastrointestinal differentiation marker expression in extrahepatic CCA based on tumor location. We examined the expression of gastrointestinal differentiation markers in resected perihilar (n = 30) and distal (n = 54) CCAs based on the immunohistochemical expression of the following markers: MUC2, MUC5AC, MUC6, CD10, CDX-2, and cytokeratin 20. Expression scores were determined semiquantitatively based on the rate of positively stained cells. Furthermore, we performed hierarchical clustering of the CCAs based on the immunohistochemical expression scores to evaluate differences in the expression patterns of the 6 gastrointestinal differentiation markers. Consequently, perihilar and distal CCAs were stratified into 2 subgroups each. Among the perihilar CCAs, subgroup 1 was characterized by lower expression of MUC5AC and MUC6, a larger median tumor size, and a significantly worse prognosis compared with subgroup 2. Furthermore, the immunohistological subgroup (subgroup 1 versus 2) and TNM stage (stage III versus II) were independent predictors of patient survival. Among the distal CCAs, subgroup 1 was characterized by lower expression of MUC5AC compared with subgroup 2. We suggest that gastrointestinal differentiation marker profiles are useful for stratifying perihilar and distal CCAs. In addition, gastrointestinal differentiation markers play a crucial role in tumor development, particularly in perihilar CCA.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Distal cholangiocarcinoma; Gastrointestinal differentiation marker; Immunohistochemistry; Patient survival; Perihilar cholangiocarcinoma

Mesh:

Substances:

Year:  2019        PMID: 31401234     DOI: 10.1016/j.humpath.2019.08.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

Review 1.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

2.  Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma.

Authors:  Yasuhiro Takihata; Takahiro Einama; Kazuki Kobayashi; Takafumi Suzuki; Naoto Yonamine; Ibuki Fujinuma; Takazumi Tsunenari; Yoji Yamagishi; Toshimitsu Iwasaki; Yoichi Miyata; Eiji Shinto; Sho Ogata; Hironori Tsujimoto; Hideki Ueno; Yoji Kishi
Journal:  Oncol Lett       Date:  2021-03-23       Impact factor: 2.967

3.  Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse.

Authors:  Suyanee Thongchot; Chiara Vidoni; Alessandra Ferraresi; Watcharin Loilome; Narong Khuntikeo; Sakkarn Sangkhamanon; Attapol Titapun; Ciro Isidoro; Nisana Namwat
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

4.  Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma.

Authors:  Maximilian N Kinzler; Falko Schulze; Steffen Gretser; Nada Abedin; Jörg Trojan; Stefan Zeuzem; Andreas A Schnitzbauer; Dirk Walter; Peter J Wild; Katrin Bankov
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.